戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 these, 135 (59.5%) studies were supported by pharmaceutical industry.
2 ct that could be of interest for food and/or pharmaceutical industry.
3  amines are valuable building blocks for the pharmaceutical industry.
4 try (HDX-MS) is increasingly utilized in the pharmaceutical industry.
5 uct development and quality assurance in the pharmaceutical industry.
6 gists received substantial payments from the pharmaceutical industry.
7 cial relationship between physicians and the pharmaceutical industry.
8 enting important class types relevant to the pharmaceutical industry.
9 GPCRs have been successfully targeted by the pharmaceutical industry.
10 resented separately given its large, generic pharmaceutical industry.
11 stion of major practical significance in the pharmaceutical industry.
12 ch and preclinical toxicity screening by the pharmaceutical industry.
13 ves as a novel potential drug target for the pharmaceutical industry.
14 es, which are of significant interest in the pharmaceutical industry.
15  therapeutic areas is of key interest to the pharmaceutical industry.
16 uccess, delivering blockbuster sales for the pharmaceutical industry.
17 sent, therefore, an important target for the pharmaceutical industry.
18  have potential applications in the food and pharmaceutical industry.
19 in therapeutics are rapidly transforming the pharmaceutical industry.
20 locks for bioactive compounds as well as the pharmaceutical industry.
21 t times with much greater involvement of the pharmaceutical industry.
22 he individual, the healthcare system and the pharmaceutical industry.
23 e considered as attractive scaffolds for the pharmaceutical industry.
24 nds of wide use in organic chemistry and the pharmaceutical industry.
25 al approaches that are currently used in the pharmaceutical industry.
26 ls has garnered significant attention by the pharmaceutical industry.
27 ne in the creativity and productivity of the pharmaceutical industry.
28 ely studied drug discovery target within the pharmaceutical industry.
29 drug discovery is a thriving strategy in the pharmaceutical industry.
30 the broad adoption of these reactions by the pharmaceutical industry.
31 ntly an area of significant interest for the pharmaceutical industry.
32 his challenge are highly sought after by the pharmaceutical industry.
33  exploit this neutral biopolymer in food and pharmaceutical industry.
34 pharmaceuticals and to save resources in the pharmaceutical industry.
35 y potential applications in the agrifood and pharmaceutical industry.
36 into production mode within academia and the pharmaceutical industry.
37 , consequently, are of great interest in the pharmaceutical industry.
38 nsiderable interest in both academia and the pharmaceutical industry.
39 on of enantiopure lactones or esters used in pharmaceutical industry.
40 ents one of the major antitarget concerns in pharmaceutical industry.
41 a recipient of wastewater effluents from the pharmaceutical industry.
42  can produce glycoconjugates relevant to the pharmaceutical industry.
43 dered this the fastest growing sector in the pharmaceutical industry.
44 ators on US clinical trials sponsored by the pharmaceutical industry.
45 rent real-world separation problems from the pharmaceutical industry.
46  of processes and products, primarily in the pharmaceutical industry.
47 s (APIs) manipulated and/or produced in this pharmaceutical industry.
48 d the standard technologies employed by, the pharmaceutical industry.
49 ine materials is a principle interest of the pharmaceutical industry.
50 st important classes of drug targets for the pharmaceutical industry.
51 he manufacturing and marketing skills of the pharmaceutical industry.
52 zed solids is of significant interest in the pharmaceutical industry.
53 were unlikely to be developed further by the pharmaceutical industry.
54 libraries are an integral element in today's pharmaceutical industry.
55 g discovery from Western governments and the pharmaceutical industry.
56 ug discovery and development programs in the pharmaceutical industry.
57 al, patients, government regulators, and the pharmaceutical industry.
58 n animal studies and clinical trials for the pharmaceutical industry.
59 in a decrease of environmental impact in the pharmaceutical industry.
60 ent and manufacturing organizations; and the pharmaceutical industry.
61 ation and validation is a requirement in the pharmaceutical industry.
62 olic disorders is highly sought after by the pharmaceutical industry.
63 nisms in obesity and diabetes, and in R&D of pharmaceutical industry.
64 distinct pathogens within the healthcare and pharmaceutical industry.
65 ble tool to many researchers in academia and pharmaceutical industry.
66 yanins and has many applications in food and pharmaceutical industry.
67 attractive for industrial application in the pharmaceutical industry.
68 ing these levels is a major objective of the pharmaceutical industry.
69 antiomers is a substantial challenge for the pharmaceutical industry.
70 development of therapeutic antibodies by the pharmaceutical industry.
71  heteroaromatic systems commonly used in the pharmaceutical industry.
72 y intermediates in organic synthesis and the pharmaceutical industry.
73 t but immensely worthwhile challenge for the pharmaceutical industry.
74 es is becoming increasingly important in the pharmaceutical industry.
75 g structural motifs, highly desirable by the pharmaceutical industry.
76 ning protein 4, a prominent cancer target in pharmaceutical industry.
77 ations and applications of kenaf in food and pharmaceuticals industry.
78  find applications in the food, cosmetic and pharmaceutical industries.
79       Extracts could be used in the food and pharmaceutical industries.
80 c protein could be used in food, cosmetic or pharmaceutical industries.
81 ive substance in the food, nutraceutical and pharmaceutical industries.
82 y-products to recover compounds for food and pharmaceutical industries.
83  several end-users in the food, cosmetic and pharmaceutical industries.
84 C-N bonds, which are of high interest to the pharmaceutical industries.
85 o the petroleum, materials, agricultural and pharmaceutical industries.
86 nd theoretical interest for the chemical and pharmaceutical industries.
87 rch in academia and in the biotechnology and pharmaceutical industries.
88  products development in food, cosmetic, and pharmaceutical industries.
89 at potential for application in the food and pharmaceutical industries.
90 d for cryoEM to become widely interesting to pharmaceutical industries.
91 urces, has many applications in the food and pharmaceutical industries.
92 s, that could be of interest in the food and pharmaceutical industries.
93  sources of antioxidants for use in food and pharmaceutical industries.
94  parts of durian fruits can benefit food and pharmaceutical industries.
95 ration in several materials for the food and pharmaceutical industries.
96 for their applications in food, cosmetic and pharmaceutical industries.
97 ducts are of interest in food, cosmetics and pharmaceutical industries.
98 y have potential for applications in food or pharmaceutical industries.
99 hen extracted and used in food, cosmetic and pharmaceutical industries.
100 me of increasing importance for chemical and pharmaceutical industries.
101 moting antioxidants for use by both food and pharmaceutical industries.
102  device for applications in the clinical and pharmaceutical industries.
103 ol synthesis is critical to the chemical and pharmaceutical industries.
104 wing applicability to the food, cosmetic and pharmaceutical industries.
105 ned products for application in the food and pharmaceutical industries.
106 of valuable bioactive compounds for food and pharmaceutical industries.
107 umerous applications in the agricultural and pharmaceutical industries.
108 d anthocyanidins largely adopted in food and pharmaceutical industries.
109 ial applications, especially in cosmetic and pharmaceutical industries.
110 ommercial uses in the flavor, fragrance, and pharmaceutical industries.
111 long duration for aeronautical, medical, and pharmaceutical industries.
112  anticancer agent for future applications in pharmaceutical industries.
113 n to leadership training in the academic and pharmaceutical industries.
114 able biomass in the food, feed, chemical and pharmaceutical industries.
115 crobial sanitation technologies for food and pharmaceutical industries.
116 A prices due to negotiation between BMoH and pharmaceutical industries.
117    These systems offer investigators and the pharmaceutical industry a new tool in testing the safety
118 anging market pressures being applied to the pharmaceutical industry, a greater emphasis is being mad
119 n of subject matter experts representing the pharmaceutical industry, academia, product development p
120 transplant community stakeholders, including pharmaceutical industry, academic researchers, clinician
121  practitioners, regulatory agencies, and the pharmaceutical industry aggressively seek biomarkers to
122                                      For the pharmaceutical industry, AI can improve decision-making
123 iences, crop protection, drug discovery, and pharmaceutical industries, among others.
124 ovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
125                    EU/European Federation of Pharmaceutical Industries and Associations Innovative Me
126                                         Teva Pharmaceutical Industries and H Lundbeck A/S.
127 tform chemical in the food, agriculture, and pharmaceutical industries and is mainly biosynthesized b
128 d collaborates with the oral health care and pharmaceutical industries and medical PBRNs to advance t
129 overy of valuable metabolites in biorefinery pharmaceutical industries and the disinfection of large-
130 ed separately because it has a large generic pharmaceutical industry and a higher availability of med
131 plains the increasing engagement of both the pharmaceutical industry and academia towards the discove
132 ral facet of drug discovery campaigns in the pharmaceutical industry and academia.
133 rization of recombinant glycoproteins in the pharmaceutical industry and academic biomedicine.
134  There has been little consensus between the pharmaceutical industry and academic communities concern
135 natorial chemistry is now commonplace in the pharmaceutical industry and applied rigorously in the di
136 mpounds and presents major challenges to the pharmaceutical industry and clinical medicine.
137  discovery have dogged our standing with the pharmaceutical industry and grant-giving bodies.
138 applications of pharmacogenomics both in the pharmaceutical industry and in a clinical setting.
139 efforts to design its inhibitors both in the pharmaceutical industry and in academia.
140 Drug Administration provides guidance to the pharmaceutical industry and others designing randomized
141 l focus on the current challenges facing the pharmaceutical industry and Pharma's responses to addres
142 l focus on the current challenges facing the pharmaceutical industry and Pharma's responses, focusing
143 t paradigm is now well established among the pharmaceutical industry and regulatory agencies.
144 T disintegration time which will provide the pharmaceutical industry and regulatory authorities acros
145 drug metabolism and pharmacokinetics for the pharmaceutical industry and regulatory authorities, and
146 se has received considerable interest in the pharmaceutical industry and remains a valid and interest
147 the criticisms that have been leveled at the pharmaceutical industry and summarize the supporting dat
148 ty rights, and generated clear gains for the pharmaceutical industry and the developed world.
149 issues have not encouraged investment by the pharmaceutical industry and there have been no new licen
150 d the globe, and it provides peptides to the pharmaceutical industry and to thousands of scientists w
151 hed in 2010 between the COPD Foundation, the pharmaceutical industry, and academic chronic obstructiv
152  to transform basic biological research, the pharmaceutical industry, and clinical medicine of the li
153 nd encourage synergies between academia, the pharmaceutical industry, and contract research organizat
154 prised of representatives from academia, the pharmaceutical industry, and the federal government incl
155 ve limited exposure to how the biotechnology/pharmaceutical industry approaches drug discovery and de
156 e know that clinical trials sponsored by the pharmaceutical industry are likely to exaggerate benefit
157  accuracy.Traditional approaches used in the pharmaceutical industry are not precise or versatile eno
158 quarter of C-N bond-forming reactions in the pharmaceutical industry are performed via reductive amin
159 l protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.
160 ls, and therefore, it can be of interest for pharmaceutical industries as a high-throughput BBB penet
161  extracts could be exploited in the food and pharmaceutical industries as alternative sources of natu
162 ansplant clinicians, transplant researchers, pharmaceutical industries as well as regulatory organiza
163 ost a decade, TRPV1 has been explored by the pharmaceutical industry as a potential target for exampl
164 beta-HSD1) has been widely considered by the pharmaceutical industry as a target to treat metabolic s
165  of amorphous materials, is exploited in the pharmaceutical industry as a way of increasing bioavaila
166 atients, there is a basic problem facing the pharmaceutical industry as it tries to balance the conun
167 mpounds have become of great interest to the pharmaceutical industry as they possess various biologic
168  functional ingredient in food, cosmetic and pharmaceutical industries, as well as in nanotechnology
169 ional foods, natural antioxidants and in the pharmaceutical industry, as well as other applications.
170 lic peptides are promising scaffolds for the pharmaceutical industry but their chemical synthesis is
171             Research collaborations with the pharmaceutical industry can offer valuable opportunities
172 this issue, and provides examples of how the pharmaceutical industry can support the responsible use
173                                 Although the pharmaceutical industry clearly has a leading role in de
174                Although the economics of the pharmaceutical industry continue to restrict investment
175 s produced by mammalian cell cultures in the pharmaceutical industry continues to increase, the need
176 ave potential applications in food, feed and pharmaceutical industries, contributing to the valorizat
177  emerged as a powerful synthetic tool in the pharmaceutical industry, contributing to the manufacturi
178 ility make their application in the food, or pharmaceutical, industry difficult.
179                       The development of the pharmaceutical industry, driven by progress in chemistry
180  clinical and translational researchers, the pharmaceutical industry, drug regulators, and patients a
181 n the agricultural, food, personal care, and pharmaceutical industries due to their cost effectivenes
182 rom soil bacteria and are of interest in the pharmaceutical industry due to their potent activity aga
183 get of intensive research efforts across the pharmaceutical industry, due to its potential for the tr
184 e than three decades of intense research and pharmaceutical industry efforts, a clinically effective
185  2013, assembled academic, public health and pharmaceutical industry experts to assess the challenges
186 old" solid-state chemistry fields, as in the pharmaceutical industry field, where they represent a wa
187                                          The pharmaceutical industry focuses the bulk of its efforts
188 Encapsulation is an important technology for pharmaceutical industry, food production, et cetera.
189 is a technique attractive for use within the pharmaceutical industry for at-line determination of res
190 ses the required detection limits set by the pharmaceutical industry for HZ detection in the presence
191 n shown to be a powerful strategy within the pharmaceutical industry for increasing throughput while
192 nhibition of kinases has been pursued by the pharmaceutical industry for over 20 years.
193 of metabolic disease has been pursued by the pharmaceutical industry for some time.
194 achieve the required detection limits by the pharmaceutical industry for the detection of HZ in the p
195 logy is a powerful tool commonly used by the pharmaceutical industry for the identification of compou
196 alysis has become an important method in the pharmaceutical industry for the incorporation of new fun
197 nsiderable attention from clinicians and the pharmaceutical industry for the management of hyperchole
198            It is extensively used across the pharmaceutical industry for the quantitative analysis of
199 ceutical ingredients (APIs) from formulating pharmaceutical industries (FPIs) were investigated for t
200  chemistry and discusses applications to the pharmaceutical industry, from discovery to manufacturing
201                                          The pharmaceutical industry has been desperately searching f
202 e proteins as drug targets, and although the pharmaceutical industry has been focusing on these recep
203  of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role
204                                          The pharmaceutical industry has considerable interest in PDE
205                                          The pharmaceutical industry has great interest in organic mo
206            Research in both academia and the pharmaceutical industry has led to the development of se
207                                          The pharmaceutical industry has made improvements to mitigat
208 global delivery of novel treatments from the pharmaceutical industry has plunged to the level of the
209 he basis of compelling genetic evidence, the pharmaceutical industry has put a large emphasis on brai
210                                          The pharmaceutical industry has put much effort into the dev
211 valence and enormous unmet medical need, the pharmaceutical industry has recently de-emphasized neuro
212                                          The pharmaceutical industry has recognized that many drug-li
213                                          The pharmaceutical industry has responded to this challenge
214                              For decades the pharmaceutical industry has shown preference for synthet
215                                          The pharmaceutical industry has significantly contributed to
216                  Despite these advances, the pharmaceutical industry has yet to translate breakthroug
217                          Neurologists in the pharmaceutical industry have an attractive and rewarding
218 ll inevitably increase dramatically, and the pharmaceutical industry, healthcare providers, patient a
219 pean Medicines Agency issued guidance to the pharmaceutical industry in 2008.
220 razine (HZ) is of critical importance in the pharmaceutical industry in order to uphold drug safety.
221                Nowadays, the interest of the pharmaceutical industry in peptide- and protein-based th
222          By contrast, the rise of the modern pharmaceutical industry in the past century has been bas
223  peptides, has attracted the interest of the pharmaceutical industry in these molecules as potential
224               A major challenge for food and pharmaceutical industries is the engineering of nanostru
225                    The surging growth of the pharmaceutical industry is a result of the rapidly incre
226                                          The pharmaceutical industry is currently focused on developi
227                                          The pharmaceutical industry is developing increasing numbers
228                                          The pharmaceutical industry is entering a renewed period of
229                                          The pharmaceutical industry is facing enormous challenges, i
230                                          The pharmaceutical industry is facing enormous challenges, i
231 In his new book Ben Goldacre argues that the pharmaceutical industry is in poor health and in urgent
232                                          The pharmaceutical industry is reliant on a constant supply
233                                           In pharmaceutical industry, lead discovery strategies and s
234  Pectin has several purposes in the food and pharmaceutical industry making its quantification import
235 e increasingly widespread use throughout the pharmaceutical industry, mechanistic detail about the in
236 )-antihistamines currently available and the pharmaceutical industries need to keep developing H(1)-a
237        Despite substantial investment by the pharmaceutical industry over several decades, there has
238 the criticisms that have been leveled at the pharmaceutical industry over the past 3 decades and summ
239           Despite considerable effort by the pharmaceutical industry, PAR2 has proven recalcitrant to
240 velopment of new antimicrobial agents in the pharmaceutical industry poses unanticipated challenges i
241 s at diagnosis and relapse; a joint academic-pharmaceutical industry preclinical platform to help ana
242 t in therapeutic oligonucleotides across the pharmaceutical industry, pressure is increasing on drug
243                                       In the pharmaceutical industry, protein kinases have become an
244 nas' and 'Pera' can be used for cosmetic and pharmaceutical industries purposes.
245 eveloped with broad applicability across the pharmaceutical industry, ranging from advancing medicina
246 w way of thinking in the mind of physicians, pharmaceutical industry, regulators, and HTAs.
247                                          The pharmaceutical industry remains solely reliant on synthe
248 , uncertainties have persisted regarding the pharmaceutical industry's conventionally accepted approa
249 asic research expertise in academia with the pharmaceutical industry's knowledge in manufacturing and
250               Regulatory authorities and the pharmaceutical industry should allow changes of regulato
251 federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's
252                             As both food and pharmaceutical industries show growing interest in tropi
253 linical and recently marketed drugs from the pharmaceutical industry showed that all have the same co
254 s, clinicians, health care providers and the pharmaceutical industry so that we continue the pathway
255 used in a broad range of applications in the pharmaceutical industry, spanning target identification,
256 entional Trials) guideline authors (n = 16), pharmaceutical industry statisticians (n = 3), journal e
257 ylates are important polymers widely used in pharmaceutical industry such as drug coatings due to the
258 mong the FDA, academia, data owners, and the pharmaceutical industry that is responding to the need t
259 l roles and keen interest on the part of the pharmaceutical industry, the cyclooxygenases have been t
260 tient cohorts, and growing interest from the pharmaceutical industry, the field is poised to make a b
261 lishment and sustained growth of the steroid pharmaceutical industry, the production of highly functi
262 tocol for cFAE and its widespread use in the pharmaceutical industry, the reaction mechanism has not
263                                       To the pharmaceutical industry, the scaling-up of our 3D muFCA
264 addition to formulations manufactured by the pharmaceutical industry, there has been a recent interes
265                 Consequently, in the present pharmaceutical industry, there is a rapid growth in the
266 idant peptides of high interest for food and pharmaceutical industries to develop new nutraceuticals
267 on, which is critical in hospitals, food and pharmaceutical industries to help minimize nosocomial in
268 rugs is considered by decision-makers in the pharmaceutical industry to be the most appealing route o
269 ty crisis in drug discovery has prompted the pharmaceutical industry to decentralize R&D, which is no
270      Despite very significant efforts by the pharmaceutical industry to develop drugs, with over 50 s
271 his research will be useful for the food and pharmaceutical industry to develop soya lecithin and Twe
272 tcomes but has catalyzed the interest in the pharmaceutical industry to develop the next generation o
273  Considerable efforts are being spent in the pharmaceutical industry to identify therapeutic approach
274 e cyclic oligosaccharides widely used in the pharmaceutical industry to improve drug delivery and to
275 edicinal chemistry teams in academia and the pharmaceutical industry to improve potency, physicochemi
276 ced in the USA and Europe that encourage the pharmaceutical industry to invest in targets that might
277 lative change, substantial incentives to the pharmaceutical industry to invest in the ultra-rare dise
278           There is an increasing need in the pharmaceutical industry to reduce drug failure at late s
279 ines has forced the scientific community and pharmaceutical industry to take actions in the quest for
280 d dramatically given the recent entry of the pharmaceutical industry to this arena.
281 lders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domai
282 ensive efforts, within both academia and the pharmaceutical industry, to introduce new treatments to
283 put screening campaigns,in particular in the pharmaceutical industry, to make the most out of the rec
284 Serono, Bayer Schering Pharmaceuticals, Teva Pharmaceuticals Industries, UK National Institute of Hea
285 municipal, hospitals, animal production, and pharmaceutical industries) ultimately are discharged int
286                                          The pharmaceutical industry uses various solvents to increas
287                                            A pharmaceutical industry viewpoint on how the fundamental
288                        The studies funded by pharmaceutical industry were less likely to be stopped e
289 intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi met
290 onsiderable application, particularly in the pharmaceutical industry where there is growing awareness
291 ions, therefore, are of high interest to the pharmaceutical industry, where lead compounds in drug de
292 applications in multiple areas including the pharmaceutical industry, where Raman spectroscopy is com
293 containing molecules has proliferated in the pharmaceutical industry, where the incorporation of halo
294 attrition rates of lead compounds within the pharmaceutical industry, which are often a result of scr
295 of dramatic variability in response, and the pharmaceutical industry, which must develop new drugs de
296 enges that the research, the clinic, and the pharmaceutical industry will face in developing efficien
297       Partnership between clinicians and the pharmaceutical industry with a focus on antimicrobial st
298 s one of the highest growing segments of the pharmaceutical industry with an estimated global market
299  interest in therapeutic peptides within the pharmaceutical industry with more than 50 peptide drugs
300 ld be considered as ready-to-use in food and pharmaceutical industry without demanding and expensive

 
Page Top